Introduction: The present study evaluates CD30 expression by immunohistochemistry (IHQ) in 216 patients with de novo DLBCL.Methods: CD30 expression was assessed retrospectively in all cases by IHQ. More than >0% and >20% of CD30 expression in the malignant cells were used as a cut-off for positivity. Survival was analysed in 176 patients treated with R-CHOP/R-CHOP-like regimens.Results: CD30 expression >0% was found in 66 (31%) patients, and >20% in 41 (19%). Younger patients <60 years (p = 0.03), good performance status (p = 0.04), and non-GCB subtype (p = 0.004) correlated with CD30 expression. No significant differences were found in overall survival and progression-free survival (PFS), although there was a trend towards better PFS in CD30-positive patients (p = 0.07). Among 7 patients with Epstein-Barr virus (EBV)-positive-DLBCL, CD30 was expressed in 71%, and 2-year PFS significantly inferior compared with CD30-positive EBV-negative-DLBCL patients (p = 0.01).Conclusion: CD30 is expressed in 30% of DLBCL patients, in whom targeted therapy with an anti-CD30 monoclonal antibody could be explored. CD30 is expressed more frequently younger patients, with better performance status and in the non-GCB subtype and its expression trends towards a better PFS. No significant differences regarding characteristics at diagnosis or prognosis were found between groups with different cut-off for positivity.

中文翻译：

---

从头开始弥漫性大B细胞淋巴瘤（DLBCL）中CD30表达的临床病理特征和预后意义：从单一机构获得一系列均一的结果。

简介：本研究通过免疫组织化学（IHQ）评价了216例从头DLBCL患者的CD30表达。方法：IHQ对所有病例的CD30表达进行了回顾性评估。恶性细胞中大于30％的CD30表达和大于20％的CD30被用作阳性的临界值。分析了176例接受R-CHOP / R-CHOP方案治疗的患者的生存率。结果：66例（31％）患者中CD30表达> 0％，41例（19％）CD20表达> 20％。<60岁的年轻患者（p = 0.03），良好的工作状态（p = 0.04）和非GCB亚型（p = 0.004）与CD30表达相关。尽管总生存率和无进展生存期（PFS）没有发现显着差异，但CD30阳性患者的PFS有改善的趋势（p = 0.07）。在7例爱泼斯坦-巴尔病毒（EBV）阳性-DLBCL患者中，与CD30阳性EBV阴性-DLBCL患者相比，CD30的表达率为71％，而2年PFS明显较差（p = 0.01）。结论：CD30在30％的DLBCL患者中表达，接受靶向治疗的是抗-CD30单克隆抗体可以被探索。CD30在年轻患者中更频繁地表达，具有更好的表现状态，并且在非GCB亚型中表达，并且其表达趋势趋向于更好的PFS。阳性截止值不同的组之间在诊断或预后特征方面无显着差异。CD30在年轻患者中更频繁地表达，具有更好的表现状态，并且在非GCB亚型中表达，并且其表达趋势趋向于更好的PFS。阳性截止值不同的组之间在诊断或预后特征方面无显着差异。CD30在年轻患者中更频繁地表达，具有更好的表现状态，并且在非GCB亚型中表达，并且其表达趋势趋向于更好的PFS。阳性截止值不同的组之间在诊断或预后特征方面无显着差异。